Dr. Weeks’ Comment: Since 1993, almost 40 years, I’ve been offering tomorrow’s medicine today (scientifically validated integrative medicine, which offers the best of psychoneuroimmuological and targeted biochemical support enhancing immune response) for people with cancer and chronic degenerative illnesses. Being ahead of the curve has inspired great criticism from conventionally oriented colleagues but now we have some good news. Although high dose vitamin C has been validated in the scientific research since Linus Pauline and Abram Hoffer, we’re now getting dissemination of that information to the troops in the trenches. Recently, we see that Medscape, an organ of information for conventional medical thought, is finally explaining a little bit about the benefits of high dose, vitamin C for cancer. Note that this article is driven by the fact that patients have been inquiring of their oncologist why they’re not including high dose, vitamin C.
Here are some more compelling and inspiring research articles on the benefits of high dose IV vitamin C. HERE. and. HERE. and. HERE.
~~
IV Vitamin C With Chemo Shows Signals in Cancer Care
Edited by Medscape Staff
August 03, 2026
If you see patients asking about high-dose vitamin C (ascorbate) with chemotherapy, here’s the quick read. Early human studies suggest potential benefit in select cancers, but this remains investigational and dose dependent. Safety looks manageable with screening, and larger randomized trials are still needed.
- From Bench to Bedside
A biochemist with myelodysplastic syndromes (MDS) applied his own vitamin C science to care. He receives azacitidine on a 28-day cycle with 75 g ascorbate on select days, given back to back. He reports feeling well with near-normal counts, and his oncologist is now recruiting for an MDS trial.
- How We Got Here
Earlier oral vitamin C trials were negative, which fueled skepticism. The key miss was route and achievable levels, since oral dosing can’t reach pharmacologic concentrations. Interest returned with IV ascorbate work, and the doses studied are far beyond store-bought tablets.
- What Really Drives It
This isn’t an antioxidant story at treatment doses. IV ascorbate can reach near 20 mM and behaves as a prooxidant that is thought to generate hydrogen peroxide around tumors. Preclinical data show selective damage in tumor cells, and human studies confirm achievable millimolar blood levels.
Key Points
- IV ascorbate + chemo remains investigational; phase 3 confirmation needed.
- Oral vitamin C trials were negative; IV route achieves pharmacologic levels.
- At treatment doses, IV ascorbate acts as prooxidant; H2O2-mediated tumor injury proposed.
- Early signals: metastatic pancreatic cancer survival ↑; glioblastoma/bladder signals; colorectal trial negative.
- Safety usually mild; screen G6PD deficiency, renal disease, kidney stones; target 15–20 mM.
Which cancers show strongest IV ascorbate response signals?
How does IV ascorbate alter tumor redox biology?
What predicts benefit from pharmacologic ascorbate therapy?
- Signals in Humans
Early studies hint at benefit across several cancers. In metastatic pancreatic cancer, 75 g three times weekly was associated with improved survival. Glioblastoma and bladder signals emerged, while a colorectal trial was negative overall.
- Safety and Next Steps
If you consider this treatment, dose matters and blood levels should reach 15 to 20 mM. Adverse events are usually mild; screen for G6PD, renal disease, and kidney stones. Effectiveness needs phase 3 confirmation, and funding remains a barrier despite low per-dose cost.
Bottom Line
High-dose IV ascorbate remains investigational but shows signals worth watching. If you discuss it with patients, emphasize dosing to reach pharmacologic levels and screen carefully for safety. Consider referral to trials while we wait for phase 3 confirmation and funding solutions.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.